Complement analysis in clinic and research

Advances in Experimental Medicine and Biology

Volumn 586, Issue , 2006, Pages 361-380

  Mollnes, Tom E ^a   Kirschfink, Michael ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934440005     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-34134-X_24     Document Type: Conference Paper

References (91)

1. M. J. Walport. Advances in immunology: complement (first of two parts). N Engl J Med 344(14), 1058-1066 (2001).
2. M. J. Walport. Advances in immunology: complement (second of two parts). N Engl J Med 344(15), 1140-1144 (2001).
3. D. Mastellos and J. D. Lambris. Complement: more than a "guard" against invading pathogens? Trends Immunol 23(10), 485-491 (2002).
4. J. Kohl. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 38(2-3), 175-187 (2001).
5. Z. Fishelson, N. Donin, S. Zell, S. Schultz, and M. Kirschfink. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (MCRPs) in tumors. Mol Immunol 40(2-4), 109-123 (2003).
6. A. J. Nauta, M. R. Daha, C. VanKooten, and A. Roos. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 24(3), 148-154 (2003).
7. H. Jarva and S. Meri. Paroxysmal nocturnal haemoglobinuria: the disease and a hypothesis for a new treatment. Scand J Immunol 49(2), 119-125 (1999).
8. J. E. Figueroa and P. Densen. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4, 359-395 (1991).
9. M. J. Walport and P. J. Lachmann. Complement deficiencies and abnormalities of the complement system in systemic lupus erythematosus and related disorders. Curr Opin Rheumatol 2, 661-663 (1990).
10. S. M. Linton and B. P. Morgan. Complement activation and inhibition in experimental models of arthritis. Mol Immunol 36(13-14), 905-914 (1999).
11. P. L. McGeer and E. G. McGeer. The possible role of complement activation in Alzheimer disease. Trends Mol Med 8(11), 519-523 (2002).
12. F. Sellebjerg, I. Jaliashvili, M. Christiansen, and P. Garred. Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci 157(2), 168-174 (1998).
13. S. Sawant Mane, M. B. Clark, and C. L. Koski. In vitro demyelination by serum antibody from patients with Guillain-Barre syndrome requires terminal complement complexes. Ann Neurol 29, 397-404 (1991).
14. G. Zilow, J. A. Sturm, U. Rother, and M. Kirschfink. Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin Exp Immunol 79, 151-157 (1990).
15. T. E. Mollnes and E. Fosse. The complement system in trauma-related and ischemic tissue damage: a brief review. Shock 2, 301-310 (1994).
16. T. V. Arumugam, I. A. Shiels, T. M. Woodruff, D. N. Granger, and S. M. Taylor. The role of the complement system in ishemia-reperfusion injury. Shock 21(5), 401-409 (2004).
17. P. A. Ward. The dark side of C5A in sepsis. Nat Rev Immunol 4(2), 133-142 (2004).
18. M. Kirschfink, B. Kovacs, and K. Mottaghy. Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces. Circ Shock 40, 221-226 (1993).
19. T. E. Mollnes. Biocompatibility: Complement as mediator of tissue damage and as indicator of incompatibility. Exp Clin Immunogenet 14(1), 24-29 (1997).
20. S. C. Ross and P. Densen. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63, 243-273 (1984).
21. B. P. Morgan and A. Orren. Vaccination against meningococcus in complement-deficient individuals. Clin Exp Immunol 114(3), 327-329 (1998).
22. S. M. Linton and B. P. Morgan. Properdin deficiency and meningococcal disease - identifying those most at risk. Clin Exp Immunol 118(2), 189-191 (1999).
23. M. A. Seelen, A. Roos, J. Wieslander, T. E. Mollnes, A. G. Sjoholm, R. Wurzner, M. Loos, F. Tedesco, R. B. Sim, P. Garred, E. Alexopoulos, M. W. Turner, and M. R. Daha. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods 296(1-2), 187-198 (2005).
24. P. Garred and H. O. Madsen. Genetic susceptibility to sepsis: a possible role for mannose-binding lectin. Curr Infect Dis Rep 6(5), 367-373 (2004).
25. A. Koch, M. Melbye, P. Sorensen, P. Homoe, H. O. Madsen, K. Molbak, C. H. Hansen, L. H. Andersen, G. W. Hahn, and P. Garred. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 285(10), 1316-1321 (2001).
26. P. J. Lachmann. Complement deficiency and the pathogenesis of autoimmune immune complex disease. Chem Immunol 49, 245-263 (1990).
27. D. R. Karp. Complement and systemic lupus erythematosus. Curr Opin Rheumatol 17(5), 538-542 (2005).
28. M. C. Carroll. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol 4(10), 825-831 (2004).
29. M. C. Pickering, M. Botto, P. R. Taylor, P. J. Lachmann, and M. J. Walport. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 76, 227-324 (2000).
30. I. E. Coremans, P. E. Spronk, H. Bootsma, M. R. Daha, d. van, V, L. Kater, F. C. Breedveld, and C. G. Kallenberg. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis 26(4), 595-601 (1995).
31. G. B. Appel, H. T. Cook, G. Hageman, J. C. Jennette, M. Kashgarian, M. Kirschfink, J. D. Lambris, L. Lanning, H. U. Lutz, S. Meri, N. R. Rose, D. J. Salant, S. Sethi, R. J. Smith, W. Smoyer, H. F. Tully, S. P. Tully, P. Walker, M. Welsh, R. Wurzner, and P. F. Zipfel. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 16(5), 1392-1403 (2005).
32. M. R. Daha, D. T. Fearon, and K. F. Austen. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 116, 1-7 (1976).
33. M. A. Dragon-Durey, V. Fremeaux-Bacchi, C. Loirat, J. Blouin, P. Niaudet, G. Deschenes, P. Coppo, F. W. Herman, and L. Weiss. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 15(3), 787-795 (2004).
34. J. J. Roord, R. A. van Diemen van Steenvoorde, H. J. Schuurman, G. T. Rijkers, B. J. Zegers, F. H. Gmelig Meyling, and J. W. Stoop. Membranoproliferative glomerulonephritis in a patient with congenital deficiency of the third component of complement: effect of treatment with plasma. Am J Kidney Dis 13, 413-417 (1989).
35. T. S. Jokiranta, A. Solomon, M. K. Pangburn, P. F. Zipfel, and S. Meri. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 163(8), 4590-4596 (1999).
36. P. F. Zipfel. Hemolytic uremic syndrome: how do factor H mutants mediate endothelial damage? Trends Immunol 22(7), 345-348 (2001).
37. M. Cicardi, L. Bergamaschini, M. Cugno, A. Beretta, L. C. Zingale, M. Colombo, and A. Agostoni. Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology 199(2), 366-376 (1998).
38. U. C. Nzeako, E. Frigas, and W. J. Tremaine. Hereditary angioedema - A broad review for clinicians. Arch Intern Med 161(20), 2417-2429 (2001).
39. E. Pappalardo, L. C. Zingale, A. Terlizzi, A. Zanichelli, A. Folcioni, and M. Cicardi. Mechanisms of C1-inhibitor deficiency. Immunobiology 205(4-5), 542-551 (2002).
40. J. Alsenz, K. Bork, and M. Loos. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 316, 1360-1366 (1987).
41. P. Boccuni, V. L. Del, N. R. Di, and B. Rotoli. Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria. Crit Rev Oncol Hematol 33(1), 25-43 (2000).
42. Y. L. Kwong, C. P. Lee, T. K. Chan, and L. C. Chan. Flow cytometric measurement of glycosylphosphatidylinositol-linked surface proteins on blood cells of patients with paroxysmal nocturnal hemoglobinuria. Am J Clin Pathol 102, 30-35 (1994).
43. S. V. Petersen, S. Thiel, L. Jensen, R. Steffensen, and J. C. Jensenius. An assay for the mannan-binding lectin pathway of complement activation. J Immunol Methods 257(1-2), 107-116 (2001).
44. S. Munkvad, J. Jespersen, J. Gram, K. Overgaard, and M. Ranby. Effects of methylamine and heparin on a rapid chromogenic assay of C1-esterase inhibitor in plasma. Clin Chem 36, 737-741 (1990).
45. P. F. Zipfel, J. Hellwage, M. A. Friese, G. Hegasy, S. T. Jokiranta, and S. Meri. Factor H and disease: a complement regulator affects vital body functions. Mol Immunol 36(4-5), 241-248 (1999).
46. D. Kavanagh, E. J. Kemp, E. Mayland, R. J. Winney, J. S. Duffield, G. Warwick, A. Richards, R. Ward, J. A. Goodship, and T. H. Goodship. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 16(7), 2150-2155 (2005).
47. D. Kavanagh, E. J. Kemp, E. Mayland, R. J. Winney, J. S. Duffield, G. Warwick, A. Richards, R. Ward, J. A. Goodship, and T. H. Goodship. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 16(7), 2150-2155 (2005).
48. T. E. Mollnes and M. Harboe. Neoepitope expression during complement activation - a model for detecting antigenic changes in proteins and activation of cascades. Immunologist 1, 43-49 (1993).
49. T. E. Mollnes. Analysis of in vivo complement activation. In: Weir's handbook of experimental immunology. Eds. L. A. Herzenberg, D. M. Weir, Herzenberg, L, Blackwell C. 78.1-78.8. Blackwell Science. Boston. (1997).
50. H. Hartmann, B. Lubbers, M. Casaretto, W. Bautsch, A. Klos, and J. Kohl. Rapid quantification of C3A and C5A using a combination of chromatographic and immunoassay procedures. J Immunol Methods 166, 35-44 (1993).
51. H. Fure, E. W. Nielsen, C. E. Hack, and T. E. Mollnes. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand J Immunol 46(6), 553-557 (1997).
52. H. Fure, E. W. Nielsen, C. E. Hack, and T. E. Mollnes. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand J Immunol 46(6), 553-557 (1997).
53. T. E. Mollnes, P. Garred, and G. Bergseth. Effect of time, temperature and anticoagulants on in vitro complement activation: Consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol 73, 484-488 (1988).
54. J. L. Wagner and T. E. Hugli. Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids. Anal Biochem 136, 75-88 (1984).
55. M. Oppermann and O. Gotze. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. Immunology 82, 516-521 (1994).
56. B. Teisner, I. Brandslund, N. Grunnet, L. K. Hansen, J. Thellesen, and S. E. Svehag. Acute complement activation during an anaphylactoid reaction to blood transfusion and the disappearance rate of C3c and C3d from the circulation. J Clin Lab Immunol 12, 63-67 (1983).
57. T. E. Mollnes. Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex. Complement 2, 156-164 (1985).
58. R. Deppisch, V. Schmitt, J. Bommer, G. M. Hansch, E. Ritz, and E. W. Rauterberg. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int 37, 696-706 (1990).
59. W. Nurnberger and S. Bhakdi. Plasma C3d/C3 quotient as a parameter for in vivo complement activation. J Immunol Methods 74, 87-91 (1984).
60. J. Lule, G. J. Fournie, and J. J. Conte. Quantification of large C3 fragments as an index of complement activation in mice. II. In vivo studies. Complement 1, 103-107 (1984).
61. T. E. Mollnes, O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegard, J. Kohl, and J. D. Lambris. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100(5), 1869-1877 (2002).
62. S. Wan, J. L. LeClerc, and J. L. Vincent. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 112(3), 676-692 (1997).
63. J. C. Chen, S. A. Rollins, S. K. Shernan, S. Boyce, K. Allen, A. Wallace, K. J. Malloy, J. S. Eng, R. W. Colman, and J. C. Fitch. Pharmacologic C5-complement suppression reduces blood loss during on-pump cardiac surgery. J Card Surg 20(1), 35-41 (2005).
64. C. J. Strang, H. S. Auerbach, and F. S. Rosen. C1s-induced vascular permeability in C2-deficient guinea pigs. J Immunol 137(2), 631-635 (1986).
65. R. Ameratunga, J. A. Winkelstein, L. Brody, M. Binns, L. C. Cork, P. Colombani, and D. Valle. Molecular analysis of the third component of canine complement (C3) and identification of the mutation responsible for hereditary canine C3 deficiency. J Immunol 160(6), 2824-2830 (1998).
66. R. A. Wetsel, D. T. Fleischer, and D. L. Haviland. Deficiency of the murine fifth complement component (C5): a 2-base pair gene deletion in a 5′-exon. J Biol Chem 265(5), 2435-2440 (1990).
67. V. M. Holers. Phenotypes of complement knockouts. Immunopharmacology 49(1-2), 125-131 (2000).
68. A. Circolo, G. Garnier, W. Fukuda, X. Wang, T. Hidvegi, A. J. Szalai, D. E. Briles, J. E. Volanakis, R. A. Wetsel, and H. R. Colten. Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology 42(1-3), 135-149 (1999).
69. M. B. Fischer, M. Ma, S. Goerg, X. Zhou, J. Xia, O. Finco, S. Han, G. Kelsoe, R. G. Howard, T. L. Rothstein, E. Kremmer, F. S. Rosen, and M. C. Carroll. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 157(2), 549-556 (1996).
70. M. Matsumoto, W. Fukuda, A. Circolo, J. Goellner, J. Strauss- Schoenberger, X. Wang, S. Fujita, T. Hidvegi, D. D. Chaplin, and H. R. Colten. Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci USA 94(16), 8720-8725 (1997).
71. J. Kildsgaard, T. J. Hollmann, K. W. Matthews, K. Bian, F. Murad, and R. A. Wetsel. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Immunol 165(10), 5406-5409 (2000).
72. S. E. Applequist, J. Dahlstrom, N. Jiang, H. Molina, and B. Heyman. Antibody production in mice deficient for complement receptors 1 and 2 can be induced by IgG/Ag and IgE/Ag, but not IgM/Ag complexes. J Immunol 165(5), 2398-2403 (2000).
73. C. W. Vogel, C. A. Smith, and H. J. Muller Eberhard. Cobra venom factor: structural homology with the third component of human complement. J Immunol 133, 3235-3241 (1984).
74. P. W. Mathieson, F. J. Qasim, S. Thiru, R. G. Oldroyd, and D. B. G. Oliveira. Effects of decomplementation with cobra venom factor on experimental vasculitis. Clin Exp Immunol 97, 474-477 (1994).
75. J. F. Regal, D. G. Fraser, D. E. Anderson, and L. E. Solem. Enhancement of Antigen-Induced Bronchoconstriction After intravascular complement activation with cobra venom factor-reversal by granulocyte depletion. J Immunol 150, 3496-3505 (1993).
76. T. E. Mollnes and M. Kirschfink. Strategies of therapeutic complement inhibition. Mol Immunol 43(1-2), 107-121 (2006).
77. D. A. Higgins and D. J. Langley. A comparative study of complement activation. Vet Immunol Immunopathol 9(1), 37-51 (1985).
78. O. Barta and N. L. Hubbert. Testing of hemolytic complement components in domestic animals. Am J Vet Res 39(8), 1303-1308 (1978).
79. C. Ish, G. L. Ong, N. Desai, and M. J. Mattes. The specificity of alternative complement pathway-mediated lysis of erythrocytes: a survey of complement and target cells from 25 species. Scand J Immunol 38, 113-122 (1993).
80. S. Tanaka, F. Kitamura, and T. Suzuki. Studies on the hemolytic activity of the classical and alternative pathway of complement in various animal species. Complement 4(1), 33-41 (1987).
81. C. Link, H. Hawlisch, A. M. Z. Vilsendorf, S. Gyleruz, E. Nagel, and J. Kohl. Selection of phage-displayed anti-guinea pig C5 or C5a antibodies and their application in xenotransplantation. Mol Immunol 36(18), 1235-1247 (1999).
82. H. Hawlisch, M. A. Z. Vilsendorf, W. Bautsch, A. Klos, and J. Kohl. Guinea pig C3 specific rabbit single chain Fv antibodies from bone marrow, spleen and blood derived phage libraries. J Immunol Methods 236(1-2), 117-131 (2000).
83. K. Bergh and O. J. Iversen. Measurement of complement activation in rabbit plasma or serum using monoclonal antibodies against C5a. Scand J Immunol 29, 333-341 (1989).
84. M. Schulze, P. J. Baker, D. T. Perkinson, R. J. Johnson, R. F. Ochi, R. A. Stahl, and W. G. Couser. Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. Kidney Int 35, 60-68 (1989).
85. D. Mastellos, J. Prechl, G. Laszlo, K. Papp, E. Olah, E. Argyropoulos, S. Franchini, R. Tudoran, M. Markiewski, J. D. Lambris, and A. Erdei. Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Mol Immunol 40(16), 1213-1221 (2004).
86. Y. Hiramatsu, N. Gikakis, J. H. Gorman, III, M. M. Khan, C. E. Hack, H. T. Velthuis, L. Sun, C. Marcinkiewicz, A. K. Rao, S. Niewiarowski, R. W. Colman, L. H. Edmunds Jr., and H. L. Anderson III. A baboon model for hematologic studies of cardiopulmonary bypass. J Lab Clin Med 130(4), 412-420 (1997).
87. T. E. Mollnes, H. Redl, K. Hogasen, A. Bengtsson, P. Garred, L. Speilberg, T. Lea, M. Oppermann, O. Gotze, and G. Schlag. Complement Activation in Septic Baboons Detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 91, 295-300 (1993).
88. M. Fung, P. G. Loubser, A. Undar, M. Mueller, C. Sun, W. N. Sun, W. K. Vaughn, and C. D. Fraser, Jr. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg 122(1), 113-122 (2001).
89. J. H. Jansen, K. Hogasen, and T. E. Mollnes. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type-II (Porcine Dense Deposit Disease). Am J Pathol 143, 1356-1365 (1993).
90. M. Windbichler, B. Echtenacher, T. Hehlgans, J. C. Jensenius, W. Schwaeble, and D. N. Mannel. Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis. Infect Immun 72(9), 5247-5252 (2004).
91. R. M. De Waal, G. Schrijver, M. J. Bogman, K. J. Assmann, and R. A. Koene. An improved sensitive and simple microassay of mouse complement. J Immunol Methods 108(1-2), 213-221 (1988).